Journal article
A critical review of the molecular pathophysiology of lenalidomide sensitivity in 5q − myelodysplastic syndromes
Leukemia & lymphoma, Vol.53(5), pp.779-788
05/01/2012
DOI: 10.3109/10428194.2011.623255
PMID: 21955212
Abstract
The 5q deletion is a chromosomal abnormality that is observed in a subset of myelodysplastic syndromes (MDS). When isolated, this abnormality defines a specific clinical syndrome termed MDS associated with isolated deletion 5q, presenting with macrocytic anemia, normal platelet count or slight thrombocytosis, hypolobated megakaryocytes and fewer than 5% blasts in the bone marrow. MDS with the 5q deletion have a particular sensitivity to treatment with lenalidomide, a thalidomide analog. In this article, molecular changes in 5q− MDS derived from haploinsufficiency of genes encoded from the deleted region in 5q are reviewed, and mechanisms that link these molecular lesions with lenalidomide sensitivity are proposed.
Details
- Title: Subtitle
- A critical review of the molecular pathophysiology of lenalidomide sensitivity in 5q − myelodysplastic syndromes
- Creators
- Ioannis A. Voutsadakis - Centre Pluridisciplinaire d'OncologieAnne Cairoli - Service d'Hematologie, Centre Hospitalier Universitaire Vaudois
- Resource Type
- Journal article
- Publication Details
- Leukemia & lymphoma, Vol.53(5), pp.779-788
- Publisher
- Taylor & Francis
- DOI
- 10.3109/10428194.2011.623255
- PMID
- 21955212
- ISSN
- 1042-8194
- eISSN
- 1029-2403
- Number of pages
- 10
- Language
- English
- Date published
- 05/01/2012
- Academic Unit
- Internal Medicine
- Record Identifier
- 9984806507402771
Metrics
3 Record Views